Episode
Boosters for all adults, conflicting advice
- Podcast
- Dr. John Campbell
- Published
- Jul 11, 2026
- Duration seconds
- 1866
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/VG5664593104.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/boosters-for-all-adults-conflicting-advice/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dr-john-campbell-7851784/boosters-for-all-adults-conflicting-advice.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
WHO advice on boosters, Link to free download my 2 textbooks http://159.69.48.3/ https://www.youtube.com/watch?v=uGCK8Z27xd0 No country can simply vaccinate its way out of the pandemic Its not vaccine ‘or’ Its vaccines ‘and’ It makes no sense to give boosters to healthy adults (when high risk around the world are still wating for their first dose) Every day there are 6 times more booster doses administered than primary doses in poorer countries This is a scandal that must stop now Food and Drug Administration https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters https://www.cdc.gov/vaccines/acip/index.html Amended the emergency use authorizations (EUA) for Moderna and Pfizer Moderna (half of the primary dose) A single booster dose for all 18 and older Acting FDA Commissioner Janet Woodcock helps to provide continued protection against COVID-19, including the serious consequences that can occur, such as hospitalization and death At least six months after primary vaccination series At least two months after Janssen Data Supporting Effectiveness Moderna, FDA analysis Study group N= 149 from the original clinical studies who received a booster Controls group N = 1,055 two-dose series Result The antibody response against the SARS-CoV-2 virus 29 days after a booster dose of the vaccine demonstrated a booster response. Pfizer-BioNTech Study group N= 200 who received a booster Controls group Same people, one month after the two-dose primary series Result The antibody response demonstrated a booster response. FDA Evaluation of Benefits and Risks Additional real-world data, on the recently increasing number of cases of COVID-19 in the U.S. and on the risk of myocarditis and pericarditis following vaccina…